Novartis Nabs First FDA Nod in Rare Kidney Disease, But Apellis Pharma Is on Its Heels
Novartis’s Fabhalta is the first FDA-approved therapy for C3 glomerulopathy. But Apellis Pharmaceuticals’ Empaveli has superior clinical data, and that drug has been submitted for FDA review in the same rare kidney disease as well as another one that does not yet have an approved therapy. The post Novartis Nabs First FDA Nod in Rare Kidney Disease, But Apellis Pharma Is on Its Heels appeared first on MedCity News.
Novartis’s Fabhalta is the first FDA-approved therapy for C3 glomerulopathy. But Apellis Pharmaceuticals’ Empaveli has superior clinical data, and that drug has been submitted for FDA review in the same rare kidney disease as well as another one that does not yet have an approved therapy.
The post Novartis Nabs First FDA Nod in Rare Kidney Disease, But Apellis Pharma Is on Its Heels appeared first on MedCity News.
